Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

739 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA. Rafii S, et al. Among authors: kaye sb. Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005. Oncotarget. 2017. PMID: 28454085 Free PMC article.
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM. Lheureux S, et al. Clin Cancer Res. 2017 Aug 1;23(15):4086-4094. doi: 10.1158/1078-0432.CCR-16-2615. Epub 2017 Feb 21. Clin Cancer Res. 2017. PMID: 28223274 Clinical Trial.
Olaparib and somatic BRCA mutations.
George A, Banerjee S, Kaye S. George A, et al. Oncotarget. 2017 Jul 4;8(27):43598-43599. doi: 10.18632/oncotarget.18419. Oncotarget. 2017. PMID: 28611314 Free PMC article. No abstract available.
Making the best of PARP inhibitors in ovarian cancer.
Banerjee S, Kaye SB, Ashworth A. Banerjee S, et al. Among authors: kaye sb. Nat Rev Clin Oncol. 2010 Sep;7(9):508-19. doi: 10.1038/nrclinonc.2010.116. Epub 2010 Aug 10. Nat Rev Clin Oncol. 2010. PMID: 20700108 Review.
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Ang JE, et al. Among authors: kaye sb. Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6. Clin Cancer Res. 2013. PMID: 23922302
PARP inhibitors: the race is on.
Brown JS, Kaye SB, Yap TA. Brown JS, et al. Among authors: kaye sb. Br J Cancer. 2016 Mar 29;114(7):713-5. doi: 10.1038/bjc.2016.67. Br J Cancer. 2016. PMID: 27022824 Free PMC article. No abstract available.
739 results